JP2005505540A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505540A5
JP2005505540A5 JP2003522577A JP2003522577A JP2005505540A5 JP 2005505540 A5 JP2005505540 A5 JP 2005505540A5 JP 2003522577 A JP2003522577 A JP 2003522577A JP 2003522577 A JP2003522577 A JP 2003522577A JP 2005505540 A5 JP2005505540 A5 JP 2005505540A5
Authority
JP
Japan
Prior art keywords
chemotherapeutic agent
dose
agent according
administered
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003522577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505540A (ja
Filing date
Publication date
Priority claimed from AUPR7302A external-priority patent/AUPR730201A0/en
Priority claimed from AUPR9504A external-priority patent/AUPR950401A0/en
Application filed filed Critical
Priority claimed from PCT/AU2002/001160 external-priority patent/WO2003018062A1/en
Publication of JP2005505540A publication Critical patent/JP2005505540A/ja
Publication of JP2005505540A5 publication Critical patent/JP2005505540A5/ja
Pending legal-status Critical Current

Links

JP2003522577A 2001-08-27 2002-08-27 改善された治療プロトコール Pending JP2005505540A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR7302A AUPR730201A0 (en) 2001-08-27 2001-08-27 Preventive treatment for toxic side-effects caused by chemotherapeutic agents
AUPR9504A AUPR950401A0 (en) 2001-12-13 2001-12-13 Methods for treatment
PCT/AU2002/001160 WO2003018062A1 (en) 2001-08-27 2002-08-27 Improved therapeutic protocols

Publications (2)

Publication Number Publication Date
JP2005505540A JP2005505540A (ja) 2005-02-24
JP2005505540A5 true JP2005505540A5 (cg-RX-API-DMAC10.html) 2006-01-12

Family

ID=25646785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003522577A Pending JP2005505540A (ja) 2001-08-27 2002-08-27 改善された治療プロトコール

Country Status (7)

Country Link
US (2) US20050042303A1 (cg-RX-API-DMAC10.html)
EP (1) EP1427447A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005505540A (cg-RX-API-DMAC10.html)
CN (1) CN1578677A (cg-RX-API-DMAC10.html)
CA (1) CA2458856C (cg-RX-API-DMAC10.html)
MX (1) MXPA04001828A (cg-RX-API-DMAC10.html)
WO (1) WO2003018062A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
US8338648B2 (en) 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
EP1922077A4 (en) 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
US20100249064A1 (en) * 2007-09-07 2010-09-30 University Of Chicago Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan
EP2832309B1 (en) 2013-07-31 2018-03-07 Biedermann Technologies GmbH & Co. KG Implant for bones or vertebrae with self-constrained flexibility
JP2020153712A (ja) * 2019-03-18 2020-09-24 ソニーセミコンダクタソリューションズ株式会社 電流生成回路および測距システム

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US410452A (en) * 1889-09-03 Liam wiiarton
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US4665107A (en) * 1986-03-21 1987-05-12 Koh-I-Noor Rapidograph, Inc. Pigment encapsulated latex aqueous colorant dispersions
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5128450A (en) * 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
EP0952855B1 (en) * 1991-07-03 2005-07-27 Meditech Research Limited Use of hyaluronan in gene therapy
EP0563475B1 (en) * 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
CA2089621A1 (en) * 1993-02-16 1994-08-17 Rudolf Edgar Falk Formulations containing hyaluronic acid
US5847002A (en) * 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
JP2000502322A (ja) * 1995-09-14 2000-02-29 ブリストル−マイヤーズ・スクイブ・カンパニー P53−関連腫瘍の処置におけるインスリン様成長因子結合性プロテイン3(igf−bp3)
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2175282A1 (en) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
EP0891775A4 (en) * 1996-12-27 2002-07-24 Seikagaku Kogyo Co Ltd MEDICINE FOR URBAN BLADDER DISORDERS
ATE229038T1 (de) * 1997-04-04 2002-12-15 Fidia Advanced Biopolymers Srl N-sulfatierte hyaluronsäureverbindungen, ihre derivate und verfahren zu ihrer herstellung
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US20020015724A1 (en) * 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
IT1303735B1 (it) * 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
EP1140198B1 (en) * 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
IT1306643B1 (it) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2002068383A2 (en) * 2001-02-22 2002-09-06 Anika Therapeutics, Inc. Thiol-modified hyaluronan
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES

Similar Documents

Publication Publication Date Title
Quesenberry et al. Supportive care and emergency therapy
Bracey et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin‐1β
Hoeben et al. Role of endotoxin and TNF-α in the pathogenesis of experimentally induced coliform mastitis in periparturient cows
RU2557048C2 (ru) Способы терапии заболеваний легких
Bullough et al. Control of mitosis in rabbit Vx2 epidermal tumours by means of the epidermal chalone
JP2005526107A (ja) 慢性拒絶反応を予防および/または処置するための医薬
CN103180435A (zh) 用于治疗动物疾病的全身的同种异体干细胞疗法
Parbhakar et al. Depletion of pulmonary intravascular macrophages partially inhibits lipopolysaccharide-induced lung inflammation in horses
CN116133683A (zh) 通过抑制pge2降解酶15-pgdh使老化的组织和器官更生
Alberts et al. Hemithyroidectomy in a horse with confirmed hyperthyroidism
Rashid et al. Coadministration of basic fibroblast growth factor and sucrose octasulfate (sucralfate) facilitates the rat dorsal flap survival and viability
CN117904008B (zh) 一种预防和缓解抑郁的戊糖片球菌jypr-9187及其菌剂和应用
CN118286424A (zh) 来氟米特和吲哚丙酸在制备治疗或预防pd-1抑制剂所致的心脏毒性的药物中的用途
Yu et al. Effects of prenatal dexamethasone on the intestine of rats with gastroschisis
Valldecabres-Torres et al. Effects of d-cloprostenol dose and corpus luteum age on ovulation, luteal function, and morphology in nonlactating dairy cows with early corpora lutea
Rashidi et al. Minimal liver resection strongly stimulates the growth of human colon cancer in the liver of nude mice
Williams Antigen localization in lymphopenic states: I. Localization pattern following chronic thoracic duct drainage
Cepica et al. The effect of adoptive transfer of mononuclear leukocytes from an adult donor on spontaneous cell-mediated cytotoxicity and resistance to transmissible gastroenteritis in neonatal piglets
Porter et al. Lack of effect of relaxin on oxytocin output from the porcine neural lobe in vitro or in lactating sows in vivo
PT1562571E (pt) Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica
US20250000867A1 (en) Compositions and Methods for the Prevention and Treatment of Hearing Loss
Wernick et al. Pathology in practice
WO2025188928A1 (en) Administration of low-dose thiostrepton for treating cancer
Panagiotis et al. Conjugation of aldosterone by bovine and mouse liver and kidney
Dangi et al. Comparative haemato-biochemical evaluation of ultrasound guided and conventional tube cystostomy in male buffalo calves.